ArticleThe oncologist2018

FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.

Kelly J Norsworthy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.